Rapid improvement cycles for the therapeutic treatment of diabetes complications

Can rapid improvement cycles improve the therapeutic treatment of diabetes complications? A pragmatic cluster randomised controlled trial.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN56804590

Enrollment

Registered

2009-04-20

Start date

2009-06-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes complications Nutritional, Metabolic, Endocrine Diabetes

Interventions

The selected Diabetes Units will attend the 'basic course' that discusses the topic of the correct method for inputting data for the indicators that will be assessed in this study, and the method by w

participants will learn skills in using the improvement methods of the Intermountain Healthcare's Mini-advanced Training Program In Health Care Delivery Improvement designed to facilitate the developm

an electronic forum will

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Diabetes Units that use an electronic clinical record 2. Diabetes Units included in the list of centres taking part in production of the AMD Annals (AMD Annals. Diabetes care: quality indicators of diabetes care in Italy - http://www.infodiabetes.it/annali/index.asp), that offer the first representation of the practical efficacy level of the care provided by diabetology centres

Exclusion criteria

Exclusion criteria: 1. Has already taken part in quality improvement studies of the type and intensity of this one 2. Located in an area adjacent to that of enrolled Diabetes Units, excluding the worst classified Diabetes Unit

Design outcomes

Primary

Measure	Time frame
Control of cardiovascular risk factors: 1. Patients taking cholesterol-lowering drugs with low density lipoprotein cholesterol (C-LDL) greater than 100 mg/dl/total number of patients with C-LDL greater than 100 mg/dl 2. Patients undergoing anti-hypertension treatment with pulmonary arterial (PA) pressure greater than 140/90 mmHg/total number of patients with PA pressure greater than 140/90 mmHg Prescription of anti-aggregant drugs: 3. Patients undergoing anti-aggregant platelet treatment/total number of patients Primary outcomes will be assessed after 1 year and after 2 years from the start of the study.	—

Measure

Time frame

Control of cardiovascular risk factors: 1. Patients taking cholesterol-lowering drugs with low density lipoprotein cholesterol (C-LDL) greater than 100 mg/dl/total number of patients with C-LDL greater than 100 mg/dl 2. Patients undergoing anti-hypertension treatment with pulmonary arterial (PA) pressure greater than 140/90 mmHg/total number of patients with PA pressure greater than 140/90 mmHg Prescription of anti-aggregant drugs: 3. Patients undergoing anti-aggregant platelet treatment/total number of patients Primary outcomes will be assessed after 1 year and after 2 years from the start of the study.

—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

Italy

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026